Piramal Pharma Limited to Host Conference Call for Q4 and Full-Year FY2026 Results
Piramal Pharma Limited has scheduled a conference call for investors and analysts to review the company's financial performance for Q4 and the full fiscal year 2026. The call is set for April 29, 2026, beginning at 9:30 AM IST.Investors can participate using the following dial-in details for the event:
| Event | Location & Time | Telephone Number |
|---|---|---|
| Conference call on 29 th April 2026 | India - 09:30 AM IST | +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) |
| Conference call on 29 th April 2026 | India - 09:30 AM IST | 1 800 120 1221 (Toll free number) |
| Conference call on 29 th April 2026 | USA - 12:00 AM (Eastern Time - New York) | Toll free number 18667462133 |
| Conference call on 29 th April 2026 | UK - 05:00 AM (London Time) | Toll free number 08081011573 |
| Conference call on 29 th April 2026 | Singapore - 12:00 PM (Singapore Time) | Toll free number 8001012045 |
| Conference call on 29 th April 2026 | Hong Kong - 12:00 PM (Hong Kong Time) | Toll free number 800964448 |
Attendees are also advised that prior registration via the designated link can reduce waiting time at the call.
Company Overview: Piramal Pharma Ltd
Piramal Pharma Limited offers a comprehensive portfolio of differentiated products and services. The company operates through 17 global development and manufacturing facilities and maintains a global distribution network spanning over 100 countries.PPL’s business structure encompasses several key areas:
- Piramal Pharma Solutions (PPS): An integrated contract development and manufacturing organization.
- Piramal Critical Care (PCC): A specialized generics business catering to the complex hospital sector.
- Piramal Consumer Healthcare: The business segment responsible for selling over-the-counter consumer and wellness products.
Furthermore, the company's association with Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, positions it as one of the market leaders in the ophthalmology therapy area within the Indian pharmaceutical market. Piramal Pharma Ltd also holds a strategic minority investment in Yapan Bio Private Limited, which operates in the biologics/bio-therapeutics and vaccine segments.
PPLPHARMA Stock Price Movement
Shares of Piramal Pharma Limited are edging higher to ₹148.66 as of 2:27 PM today, rallying by 0.79%. The stock remains highly active in live trading, with more than 1.40 million shares traded so far in the session.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.